Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
CNBC -

The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit it to the Food and Drug Administration mid-year.

In related news